It is hypothesized that the binding of self-secreted IL7 and its cytokine receptors leads to the activation of JAK/STAT and PI3K/AKT signaling pathways to sustain HCC cellular proliferation and survival during Sorafenib treatment [13,15,16]. Here, AKT1 is linked to hepatocellular carcinoma.